EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Increased Plasma ST2 Levels Precede the Development of Severe Acute GvHD and Chronic GvHD After Pediatric Hematopoietic Stem Cell Transplantation

Nakisa Kamari-Kany iD, Sarah Weischendorff iD, Marianne Ifversen, Denise Elbæk Horan iD, Christian Enevold, Katrine Kielsen iD, Klaus Müller

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31995 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2025. Written by Nakisa Kamari-Kany and 6 co-authors. Institution: Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Major MEDLINE topics: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Interleukin-1 Receptor-Like 1 Protein, Biomarkers. Cited 3 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: The Danish Cancer Society, Danish Childhood Cancer Foundation, Novo Nordisk Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The suppressor of tumorigenesis 2 (ST2) has emerged as one of the most promising biomarkers for predicting mortality of acute graft‐versus‐host disease (aGvHD) when measured at the onset of symptoms, but detailed time course studies are needed to understand the potential of ST2 as a risk marker of both aGvHD and chronic graft‐versus‐host disease (cGvHD), potentially allowing pre‐emptive adjustment of immunosuppressive treatment. Procedure We measured ST2 levels in 117 children undergoing standard hematopoietic stem cell transplantation (HSCT) before conditioning and at regular intervals post‐HSCT.

Results

ST2 levels were significantly increased from Day +7 in patients developing aGvHD of any grade (no GvHD: 23.6 ng/mL; Grade I: 31.9 ng/mL; Grade II: 33.2 ng/mL; Grade III–IV: 59.1 ng/mL; p < 0.0001) and in patients developing aGvHD with visceral involvement (no GvHD: 23.6 ng/mL; skin only aGvHD: 24.9 ng/mL; GI and/or liver aGvHD: 59.8 ng/mL; p < 0.0001). The association between ST2 levels and aGvHD Grade II–IV was confirmed in a multivariable logistic regression analysis, adjusting for diagnosis, conditioning regimen, and donor type (OR = 1.99 per doubling in ST2, 95% confidence interval [CI] = 1.40–2.92; p = 0.00025). Patients developing cGvHD had significantly higher ST2 levels before conditioning and from Day +21 to Day +180 (all p < 0.05). ST2 levels at Day +90 were significantly associated with later development of cGvHD after adjusting for diagnosis, conditioning regimen, donor type, and prior aGvHD (HR = 2.1 per doubling in ST2, 95% CI = 1.51–2.91, p < 0.0001).

Conclusion

This study confirms ST2 as a biomarker reflecting risk of aGvHD and prognosis in pediatric allogeneic HSCT, and our findings indicate a role of ST2 as an early risk marker of cGvHD.

Subjects

MeSH terms (MEDLINE)

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationInterleukin-1 Receptor-Like 1 ProteinBiomarkersHumansChildFemaleMaleChild, PreschoolAdolescentChronic DiseaseInfantPrognosisAcute DiseaseTransplantation ConditioningFollow-Up Studies

Author keywords

ST2graft‐versus‐host diseasehematopoietic stem cell transplantationpediatrics

Substances

Interleukin-1 Receptor-Like 1 ProteinIL1RL1 protein, humanBiomarkers

Authors and institutions

  • Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Institute For Inflammation Research, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Insitute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

ORCID profiles: Nakisa Kamari-Kany, Sarah Weischendorff, Denise Elbæk Horan, Katrine Kielsen

Funding

  • The Danish Cancer Society
  • Danish Childhood Cancer Foundation
  • Novo Nordisk Foundation
  • Dagmar Marshall's Foundation
  • Tømrermester Jørgen Holm og Hustru Elisa F. Hansens Mindelegat
  • Børnecancerfonden
  • Novo Nordisk Fonden

Cite

APA

Kamari-Kany, N., Weischendorff, S., Ifversen, M., Horan, D. E., Enevold, C., Kielsen, K., & Müller, K. (2025). Increased Plasma ST2 Levels Precede the Development of Severe Acute GvHD and Chronic GvHD After Pediatric Hematopoietic Stem Cell Transplantation. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31995

Vancouver

Kamari-Kany N, Weischendorff S, Ifversen M, Horan DE, Enevold C, Kielsen K, et al. Increased Plasma ST2 Levels Precede the Development of Severe Acute GvHD and Chronic GvHD After Pediatric Hematopoietic Stem Cell Transplantation. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31995

BibTeX
@article{KamariKany2025,
  author = {Kamari-Kany, Nakisa and Weischendorff, Sarah and Ifversen, Marianne and Horan, Denise Elbæk and Enevold, Christian and Kielsen, Katrine and Müller, Klaus},
  title = {Increased Plasma ST2 Levels Precede the Development of Severe Acute GvHD and Chronic GvHD After Pediatric Hematopoietic Stem Cell Transplantation},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31995}
}
Start for free →